SubHero Banner
Text

Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) and Pifeltro (doravirine) – New drug approvals

August 30, 2018 - Merck announced the FDA approval of Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) as a complete regimen, and the FDA approval of Pifeltro (doravirine) in combination with other antiretroviral agents, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult patients with no prior antiretroviral treatment history.

Download PDF